Clinical Trial Update: A Bioequivalence Study Comparing A Fixed Dose Combination Formulation Of Myrin P Forte That Contains Rifampicin, Isoniazid, Ethambutol And Pyrazinamide Per Tablet To An Equivalent Dose Of Single Drug Reference Preparations Of Similar Combination Following Oral Administration In Healthy Adults [Phase 1]

View source ↗

Summary

A Phase 1 bioequivalence study comparing a fixed-dose combination of rifampicin, isoniazid, ethambutol and pyrazinamide per tablet to the equivalent single-drug…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Tuberculosis

Drugs mentioned

• Ethambutol (ethambutol)
• ISONIAZID (ISONIAZID)
• Myrin P Forte (rifampicin/isoniazid/ethambutol/pyrazinamide fixed-dose combination)
• Pyrazinamide (pyrazinamide)
• Rifampicin

Snippet

Sponsor: Pfizer | Conditions: Healthy Volunteers | Phase 1 | Status: COMPLETED | Results posted: 2012-03-16